TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7215768

Group type: EXPERIMENTAL
Intervention: Intravenous sulprostone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Extraamniotic injections
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Extra-amniotic injections following intramuscular injection for priming
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Priming administration
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Analgesia
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cervical dilatation
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: No effect noted
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Severe vomiting
Number of subjects: 114
Study: 31592954

Group type: EXPERIMENTAL
Intervention: LV rehabilitation (rehabilitation with a therapist)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Basic LV services (LV devices dispensed without therapy)
Number of subjects: 255
Study: 28329346

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 8 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) 200 µg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both DEC and IVM
Number of subjects: 12
Study: 26083950

Group type: EXPERIMENTAL
Intervention: DC-TC (dendritic cells loaded with antigens from irradiated autologous tumor cells)
Number of subjects: 143

Group type: COMPARATOR
Intervention: TC (irradiated tumor cells)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DC-TC (in patients with no evidence of disease at treatment start)
Number of subjects: 143

Group type: COMPARATOR
Intervention: TC (in patients with no evidence of disease at treatment start)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DC-TC (in patients with detectable metastases)
Number of subjects: 143

Group type: COMPARATOR
Intervention: TC (in patients with detectable metastases)
Number of subjects: 143
Study: 24892331

Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy (ICBT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Interstitial brachytherapy (IB)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Interstitial brachytherapy without tandem loading (IBWT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Interstitial brachytherapy with tandem source loading (IBT)
Number of subjects: 81
Study: 23173245

Group type: EXPERIMENTAL
Intervention: Acupuncture combined Chinese materia medica for tonifying shen and soothing gan (CMMTSSG)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Acupuncture combined CMMTSSG
Number of subjects: 97

Group type: COMPARATOR
Intervention: Western medicine treatment
Number of subjects: 97
Study: 20232047

Group type: EXPERIMENTAL
Intervention: HFO-TGI-high P(aw)
Number of subjects: 22

Group type: COMPARATOR
Intervention: HFO-high P(aw)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HFO-TGI-low P(aw)
Number of subjects: 22

Group type: COMPARATOR
Intervention: HFO-low P(aw)
Number of subjects: 22
Study: 17623225

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (15 ml/day, 8.1 g ALA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Safflower oil (15 ml/day, 11.2 g LA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Number of subjects: 35

Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 35
Study: 15708217

Group type: EXPERIMENTAL
Intervention: Verbal mediation during presentation of novel figural designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent verbal interference task during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent visual interference task during encoding
Number of subjects: 0
Study: 11873530

Group type: EXPERIMENTAL
Intervention: Physical training (50% of all injuries)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Running (30% of injuries linked to running)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Illness (Control)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Injuries (General)
Number of subjects: 339
Study: 10546421

Group type: EXPERIMENTAL
Intervention: Ammonium lactate 12% lotion
Number of subjects: 43

Group type: COMPARATOR
Intervention: Liposome-based moisturizing lotion
Number of subjects: 43
Study: 8696435

Group type: EXPERIMENTAL
Intervention: Early range of motion exercises starting 3 days postoperatively
Number of subjects: 57

Group type: COMPARATOR
Intervention: Late range of motion exercises starting 14 days postoperatively
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Early range of motion exercises
Number of subjects: 57
Study: 2402206

Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low Carbohydrate (LC) diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both HC and LC diets
Number of subjects: 12
Study: 7051452

Group type: EXPERIMENTAL
Intervention: 10 mg chloroquine base per kg body-weight (single dose)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: 25 mg chloroquine base per kg body-weight (given over three days)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: In vitro sensitivity testing
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Isolate requiring higher concentration
Number of subjects: 239
Study: 31109784

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-exercise control trial (CON)
Number of subjects: 30
Study: 29068863

Group type: EXPERIMENTAL
Intervention: Normal breathing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Drawing-in maneuver with normal breathing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Drawing-in maneuver with Pilates breathing
Number of subjects: 13
Study: 25378059

Group type: EXPERIMENTAL
Intervention: 3 years of subcutaneous immunotherapy (IT3)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 5 years of subcutaneous immunotherapy (IT5)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Comparison between IT3 and IT5
Number of subjects: 81
Study: 24988825

Group type: EXPERIMENTAL
Intervention: Gabapentin (started at 300 mg daily, increased to a maximum of 1800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen (started at 250 mg daily, increased to a maximum of 1500 mg)
Number of subjects: 0
Study: 23063888

Group type: EXPERIMENTAL
Intervention: Semantic condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceptual condition
Number of subjects: 0
Study: 19487623

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/5 mL) for 12 weeks, mean maximum dosage 16.5 mg/d (maximum 20 mg/d)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/5 mL) for 12 weeks
Number of subjects: 149
Study: 19558735

Group type: EXPERIMENTAL
Intervention: Optimal PEEP plus sigh breaths (twice the baseline tidal volume, plateau pressure < 40 cm H(2)O) every 25 breaths
Number of subjects: 12

Group type: COMPARATOR
Intervention: Optimal PEEP alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Optimal PEEP plus one sustained inflation (40 cm H(2)O for 30 s)
Number of subjects: 12
Study: 15936996

Group type: EXPERIMENTAL
Intervention: 40 mg of pravastatin daily
Number of subjects: 4162

Group type: COMPARATOR
Intervention: 80 mg of atorvastatin daily
Number of subjects: 4162
Study: 12230139

Group type: EXPERIMENTAL
Intervention: Participants in a slightly annoyed mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants in a neutral affective state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interaction of current mood with noise sensitivity
Number of subjects: 0
Study: 9597609

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Implant-supported overdentures
Number of subjects: 102
Study: 8186061

Group type: EXPERIMENTAL
Intervention: Litoxetine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Litoxetine 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2879175

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 20% Mannitol
Number of subjects: 19
Study: 12463779

Group type: EXPERIMENTAL
Intervention: Performance measurement feedback on claims-based measures of care process
Number of subjects: 2158

Group type: COMPARATOR
Intervention: Medical record-based measures
Number of subjects: 2158
Study: 31219734

Group type: EXPERIMENTAL
Intervention: Combination of statin, dual antiplatelet therapy, and beta-blockers prescribed to 79.6% of patients upon discharge.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system inhibitor prescribed to 67.3% of patients with LVEF ≤40%.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Beta-blocker prescribed to 91.8% of patients with LVEF ≤40%.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Regular treatment with statins in patients with prior history of CAD.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Regular treatment with antiplatelets in patients with prior history of CAD.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Regular treatment with beta-blockers in patients with prior history of CAD.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Optimal LDL-C of <70 mg/dl at admission in CAD patients.
Number of subjects: 357
Study: 29696317

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 100
Study: 26920640

Group type: EXPERIMENTAL
Intervention: Humalog® KwikPen™ 200 units/mL (IL 200 pen)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Humalog KwikPen 100 units/mL (IL 100 pen)
Number of subjects: 106
Study: 24929928

Group type: EXPERIMENTAL
Intervention: DVD (n=31)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Emotion-coaching (EC) (n=31)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Waitlist-control (n=30)
Number of subjects: 92
Study: 22705939

Group type: EXPERIMENTAL
Intervention: Mindful Movement Program (MMP) - 12 weekly sessions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no sessions)
Number of subjects: 49
Study: 20402990

Group type: EXPERIMENTAL
Intervention: Two brief motivationally focused sessions (first during incarceration, second 1 month later after community re-entry)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard of care (assessment-only condition)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Two brief motivationally focused sessions
Number of subjects: 245
Study: 18566199

Group type: EXPERIMENTAL
Intervention: WarmAir
Number of subjects: 184

Group type: COMPARATOR
Intervention: Bair Hugger
Number of subjects: 184
Study: 15988706

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12699298

Group type: EXPERIMENTAL
Intervention: Calcium enhancement of estrogen's effects, with a recommended intake of 30 to 40 mmol Ca/d and sufficient vitamin D (approximately 25 microg vitamin D/d) to maintain serum 25(OH)D levels above 80 nmol/L.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation in the presence of bone active agents.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer anabolic agents requiring higher levels of calcium repletion.
Number of subjects: 0
Study: 10480774

Group type: EXPERIMENTAL
Intervention: 600 mg alpha-lipoic acid intravenously for 3 weeks, followed by 600 mg alpha-lipoic acid three times a day orally for 6 months (A-A)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: 600 mg alpha-lipoic acid intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (A-P)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo once daily intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (P-P)
Number of subjects: 509
Study: 7815337

Group type: EXPERIMENTAL
Intervention: Cocaine HCl (80 mg/70 kg p.o.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocaine (20, 40, 80 and 120 mg/70 kg, oral and intranasal)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Triazolam (0.25 and 0.50 mg/70 kg p.o.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocaine (oral and intranasal)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocaine (training dose)
Number of subjects: 5
Study: 1745022

Group type: EXPERIMENTAL
Intervention: Polysulfone membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cuprophan membrane
Number of subjects: 0
Study: 6980657

Group type: EXPERIMENTAL
Intervention: midazolam 0.3 mg kg‐1
Number of subjects: 16

Group type: COMPARATOR
Intervention: thiopentone 3 mg kg‐1
Number of subjects: 16
Study: 31869428

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg s.c. for 3 days
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg p.o. for 3 days
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg for 10 days
Number of subjects: 793

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 793
Study: 30365262

Group type: EXPERIMENTAL
Intervention: Moxibustion + Metoclopramide (M)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Moxibustion + Haloperidol (MH)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Moxibustion + M (M)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Moxibustion + MH (MH)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Metoclopramide (M)
Number of subjects: 266
Study: 26869679

Group type: EXPERIMENTAL
Intervention: Midodrine (MH) 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: L-NAME 1 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: No drug (ND)
Number of subjects: 24
Study: 24517155

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oral hydrocortisone (OHC)
Number of subjects: 33
Study: 22356132

Group type: EXPERIMENTAL
Intervention: linagliptin + high-dose metformin
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: linagliptin + low-dose metformin
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: high-dose metformin
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: low-dose metformin
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: open-label linagliptin + high-dose metformin
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: linagliptin + metformin
Number of subjects: 791

Group type: COMPARATOR
Intervention: metformin alone
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 791
Study: 19910547

Group type: EXPERIMENTAL
Intervention: Locomotor training (LT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clinical physical therapy (PT)
Number of subjects: 20
Study: 17559146

Group type: EXPERIMENTAL
Intervention: IROX (oxaliplatin 85 mg/m² and irinotecan 200 mg/m² every 3 weeks)
Number of subjects: 383

Group type: COMPARATOR
Intervention: FOLFOX (oxaliplatin with 5-fluorouracil)
Number of subjects: 383
Study: 16293862

Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 2690

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 2690

Group type: EXPERIMENTAL
Intervention: TAM (tamoxifen)
Number of subjects: 2690

Group type: COMPARATOR
Intervention: No TAM
Number of subjects: 2690
Study: 11740322

Group type: EXPERIMENTAL
Intervention: Clarithromycin (7.5 mg/kg/dose twice a day for 7 days)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Erythromycin (13.3 mg/kg/dose three times a day for 14 days)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 153

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 153
Study: 9542477

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole
Number of subjects: 10
Study: 8061088

Group type: EXPERIMENTAL
Intervention: Interferon-beta (2 MIU/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2646839

Group type: EXPERIMENTAL
Intervention: lotrolan (0.27 osmol/kg, 280 mg J/ml)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: lopromide (0.77 osmol/kg, 370 mg J/ml)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amidotrizoate (2.1 osmol/kg, 370 mg J/ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Amidotrizoate and lopromide
Number of subjects: 15
Study: 31257160

Group type: EXPERIMENTAL
Intervention: MiRaDaSia model intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study: 28662049

Group type: EXPERIMENTAL
Intervention: SD+AMX+MET (both 500mg x 3 times daily TID) for 3 days (group B)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SD+AMX+MET (both 500mg x 3 times daily TID) for 7 days (group C)
Number of subjects: 102

Group type: COMPARATOR
Intervention: SD within 2 consecutive days and placebo for 7 days (group A)
Number of subjects: 102
Study: 26199386

Group type: EXPERIMENTAL
Intervention: Cilengitide 2,000 mg administered intravenously twice weekly (arm A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment (arm B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 21
Study: 23922748

Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil providing 15.7 g/day of TFA (trans18:1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control oil with mainly oleic acid
Number of subjects: 52
Study: 22228829

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 19476825

Group type: EXPERIMENTAL
Intervention: Conservative fluid management (CON)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Central venous catheter (CVC)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Fluid management (CON vs LIB)
Number of subjects: 244
Study: 17429507

Group type: EXPERIMENTAL
Intervention: Homeopathic preparations and practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homeopathic products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic knowledge of homeopathy
Number of subjects: 0
Study: 15110885

Group type: EXPERIMENTAL
Intervention: Chlorhexidine oral rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzydamine oral rinse
Number of subjects: 0
Study: 11018619

Group type: EXPERIMENTAL
Intervention: Preoperative biofeedback training with pelvic muscle exercise; Duration: 2 to 4 weeks before surgery; Frequency: Four times per day until surgery and resumed after catheter removal.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group performing pelvic muscle exercises without biofeedback; Received written and verbal instructions before surgery and after catheter removal.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups; Outcome measure: Rate of return of urinary control at 1, 2, 3, and 4 months after surgery.
Number of subjects: 100
Study: 8857120

Group type: EXPERIMENTAL
Intervention: Intratracheal administration of preservative-free fentanyl
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous administration of preservative-free fentanyl
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 18
Study: 1542851

Group type: EXPERIMENTAL
Intervention: Low dose (LD) radiotherapy: five times 2 Gy daily fractions to a total dose of 10 Gy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose (HD) radiotherapy: ten times 2 Gy (8 patients) or five times 3.5 Gy (20 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy initiated before and at postoperative day 4
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy initiated after postoperative day 4
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall treatment outcome
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment failures related to Brooker score
Number of subjects: 60
Study: 4003286

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 34
Study: 31423892

Group type: EXPERIMENTAL
Intervention: Descriptive expert feedback (n=39)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (n=34)
Number of subjects: 73
Study: 27522159

Group type: EXPERIMENTAL
Intervention: Early oral immunotherapy (E-OIT) at goal maintenance doses of 300 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Early oral immunotherapy (E-OIT) at goal maintenance doses of 3000 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Early oral immunotherapy (E-OIT) overall
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Early oral immunotherapy (E-OIT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched standard-care controls
Number of subjects: 40
Study: 25794018

Group type: EXPERIMENTAL
Intervention: Upward advancement of the nasolabial components (NA group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No upward advancement of the nasolabial components (LA group)
Number of subjects: 73
Study: 25433494

Group type: EXPERIMENTAL
Intervention: Health-care manager intervention (adapted)
Number of subjects: 0
Study: 22727868

Group type: EXPERIMENTAL
Intervention: Blood glucose screening using a standard protocol and glucose oxidase method in the first 48 hours after birth
Number of subjects: 514
Study: 19547761

Group type: EXPERIMENTAL
Intervention: Postoperative gabapentin (GBP) 100 mg three times per day (G3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postoperative gabapentin (GBP) 200 mg three times per day (G4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postoperative gabapentin (GBP) 300 mg three times per day (G5)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Preoperative gabapentin 600 mg/postoperative placebo (G2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Preoperative placebo/postoperative placebo (G1)
Number of subjects: 40
Study: 17306709

Group type: EXPERIMENTAL
Intervention: Stentless biological valve
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stented biological valve
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tilting disc mechanical valve
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bileaflet mechanical valve
Number of subjects: 48
Study: 15076170

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg/day
Number of subjects: 25